drugset
drugset / Trial / NCT03203811

A Phase 1, Study to Evaluate HTI-2088 Tablet

NCT03203811 ↗

Phase 1 Completed 40 enrolled Hengrui Therapeutics, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

Single Center, Randomized, Double Blind, Placebo Controlled, Single ascending dose trial at 3 levels. Ten subjects will be enrolled at each dose.

Timeline

Start
2017-02-17
Primary completion
2017-10-23
Completion
2017-10-23

Drugs

EvaluationDrugModalityDoseRoute
Subject HTI-2088 Unknown 2.5 mg Oral
Subject HTI-2088 Unknown 3.75 mg Oral
Subject HTI-2088 Unknown 5 mg Oral

Indications

diabetes mellitus